Literature DB >> 12591817

Outcome following percutaneous coronary intervention: not, so far, in our genes.

B Keavney.   

Abstract

Mesh：

Substances：

Year:  2003        PMID： 12591817      PMCID： PMC1767596          DOI： 10.1136/heart.89.3.247

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


× No keyword cloud information.
  12 in total

1.  Platelet glycoprotein receptor IIIa polymorphism PLA1/PLA2 and coronary risk: a meta-analysis.

Authors:  A Di Castelnuovo; G de Gaetano; M B Donati; L Iacoviello
Journal:  Thromb Haemost       Date:  2001-04       Impact factor: 5.249

2.  PlA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement.

Authors:  A Kastrati; A Schömig; M Seyfarth; W Koch; S Elezi; C Böttiger; J Mehilli; K Schömig; N von Beckerath
Journal:  Circulation       Date:  1999-03-02       Impact factor: 29.690

3.  PlA polymorphism of glycoprotein IIIa and risk of adverse events after coronary stent placement.

Authors:  A Kastrati; W Koch; M Gawaz; J Mehilli; C Böttiger; K Schömig; N von Beckerath; A Schömig
Journal:  J Am Coll Cardiol       Date:  2000-07       Impact factor: 24.094

4.  Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. International Studies of Infarct Survival (ISIS) Collaborators.

Authors:  B Keavney; C McKenzie; S Parish; A Palmer; S Clark; L Youngman; M Delépine; M Lathrop; R Peto; R Collins
Journal:  Lancet       Date:  2000-02-05       Impact factor: 79.321

5.  Evidence that angiotensin-converting enzyme inhibitor use diminishes the need for coronary revascularization after stenting.

Authors:  Stephen G Ellis; A Michael Lincoff; Patrick L Whitlow; Russell E Raymond; Irving Franco; Jakob P Schneider; Eric J Topol
Journal:  Am J Cardiol       Date:  2002-04-15       Impact factor: 2.778

6.  Reduced inhibition by abciximab in platelets with the PlA2 polymorphism.

Authors:  Guy L Wheeler; Gregory A Braden; Paul F Bray; Stanley J Marciniak; Mary Ann Mascelli; David C Sane
Journal:  Am Heart J       Date:  2002-01       Impact factor: 4.749

7.  Prospective evaluation of the effect of an angiotensin I converting enzyme gene polymorphism on the long term risk of major adverse cardiac events after percutaneous coronary intervention.

Authors:  M Hamon; S Fradin; A Denizet; E Filippi-Codaccioni; G Grollier; R Morello
Journal:  Heart       Date:  2003-03       Impact factor: 5.994

8.  Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group.

Authors: 
Journal:  Circulation       Date:  1992-07       Impact factor: 29.690

9.  Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction.

Authors:  F Cambien; O Poirier; L Lecerf; A Evans; J P Cambou; D Arveiler; G Luc; J M Bard; L Bara; S Ricard
Journal:  Nature       Date:  1992-10-15       Impact factor: 49.962

10.  Angiotensin converting enzyme insertion or deletion polymorphism and coronary restenosis: meta-analysis of 16 studies.

Authors:  François Bonnici; Bernard Keavney; Rory Collins; John Danesh
Journal:  BMJ       Date:  2002-09-07
View more
  3 in total

1.  High rate of in-stent restenosis after coronary intervention in carriers of the mutant mannose-binding lectin allele.

Authors:  Zsolt Bagyura; Loretta Kiss; Balázs Berta; Ágnes Szilágyi; Kristóf Hirschberg; Gábor Széplaki; Árpád Lux; Zsolt Szelid; Pál Soós; Béla Merkely
Journal:  BMC Cardiovasc Disord       Date:  2017-01-05       Impact factor: 2.298

2.  Association between VEGF Gene Polymorphisms and In-Stent Restenosis after Coronary Intervention Treated with Bare Metal Stent.

Authors:  Zsolt Bagyura; Loretta Kiss; Kristóf Hirschberg; Balázs Berta; Gábor Széplaki; Árpád Lux; Zsolt Szelid; Pál Soós; Béla Merkely
Journal:  Dis Markers       Date:  2017-03-07       Impact factor: 3.434

3.  ACE (I/D) polymorphism and response to treatment in coronary artery disease: a comprehensive database and meta-analysis involving study quality evaluation.

Authors:  Georgios Kitsios; Elias Zintzaras
Journal:  BMC Med Genet       Date:  2009-06-04       Impact factor: 2.103
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.